GETT
19.4.2021 15:02:06 CEST | Business Wire | Press release
Gett, the leading innovator in corporate Ground Transportation Management (GTM), continues to expand its marketplace of global partner fleets onto one technology platform to provide broad geographic coverage and service levels for enterprise clients.
Gett launched one of the first-ever on-demand corporate travel services in 2010, attracting Google and Disney among its first clients. With over 10 years of expertise designing seamless ground transportation experiences, Gett reduces corporate spend on ground transportation for its clients by up to 45% by offering price comparison, enforcement of travel policy compliance and optimization of back-office processes. Gett’s platform also provides other benefits, including a seamless rider experience for employers prioritizing the safety and security of their people returning to business travel following Covid-19 lockdown.
The expansion of Gett’s global platform coincides with a new supply partnership, as US taxi and e-fleet operator Curb Mobility partners with Gett and joins a portfolio of operating fleets including Lyft and Ola to access incremental high quality demand. This partnership will enable Gett to extend its presence to 65 cities in the US, expanding Gett’s marketplace to include yellow cabs as well as Gett’s existing range of vehicles and partner fleets. Bringing corporate customers a range of licensed vehicles, this new partnership supports increased demand for ground transportation as business professionals seek enhanced safety in light of the Covid-19 pandemic with the resumption of business travel.
Partner fleets already accounted for approximately one-third of B2B rides taken on Gett in Q1 2021. With the addition of Curb, and momentum in Gett’s transition from ride-hailing to an enterprise marketplace software platform, it is expected that partner fleets will represent the majority of Gett’s B2B rides globally by the end of 2021.
Gett’s largest markets are becoming lead indicators for the ground transportation and global corporate travel industries, with the progress of Covid-19 vaccination programmes in Israel and the UK. In Q1 2021, global transactions on Gett’s platform by corporate users returned to approximately 80% of the volumes seen for the corresponding period in 2020 ahead of Covid-19 lockdown restrictions. In this time period, individual markets also experienced corporate passenger volumes in excess of 2020 peaks.
Dave Waiser, CEO and co-founder of Gett commented : “Today’s partnership cements Gett’s position as a technology platform focused on corporate Ground Transportation Management (GTM), where spend is worth $79.6B globally. In recent years, we have become the GTM category leader, serving over a quarter of Fortune 500 companies.
“Our cloud-based software aggregates existing transportation providers into a single platform, helping businesses effectively manage all of their ground transportation spend. Additionally, it can expand companies’ coverage and reach by connecting them to a global transportation grid.
“We believe that bringing corporate fleets and ride-hailing companies together on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saves corporations both time and money.”
Amos Tamam, CEO at Curb commented : “As cities across the U.S. prepare for the return of international travel, our partnership with Gett will create new income opportunities for local drivers and ensure Gett's business users have access to the same safe, reliable transportation options trusted by locals. By integrating with platforms like Gett, we're aiming to make taxis more ubiquitous online by opening up new digital avenues for today’s consumers and businesses to find and book taxis.”
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
